Doxycycline as Potential Anti-cancer Agent

Area of Science:

• Oncology
• Pharmacology
• Cancer Biology

Background:

• Cancer cells thrive in hostile microenvironments, exhibiting adaptation, immune evasion, metastasis, and clonal expansion.
• Current cancer therapies often target rapidly proliferating cells, leading to side effects on healthy tissues.
• Targeted therapies aim for specific cancer vulnerabilities but may not address the adaptability of cancer cells.

Purpose of the Study:

• To introduce a novel concept in cancer pharmacology.
• To propose the repurposing of Doxycycline as a potential anticancer agent.
• To leverage Doxycycline's selective toxicity for cancer treatment.

Main Methods:

• Review of existing literature on cancer cell adaptation and microenvironment.
• Analysis of Doxycycline's pharmacological properties, particularly its selective toxicity.
• Exploration of the potential for off-label use of Doxycycline in cancer therapy.

Main Results:

• Cancer cells exhibit primitive cell-like adaptations to survive and proliferate.
• Doxycycline demonstrates selective toxicity, suggesting potential for targeting cancer cells.
• The absence of taxonomic barriers supports the investigation of Doxycycline's broad applicability.

Conclusions:

• Doxycycline presents a promising avenue for novel cancer treatment strategies.
• Repurposing Doxycycline offers a potential therapeutic approach with selective toxicity.
• Further research is warranted to validate Doxycycline's efficacy as an anticancer agent.